Unterehmen auf Watchlist setzen
Novavax
ISIN: US6700024010
WKN: A2PKMZ
Curious about what AI knows about Novavax? Just one click more
More AI Integrations
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Novavax · ISIN: US6700024010 · PR Newswire (ID: 20250227PH28845)
27 Februar 2025 10:05PM

Novavax to Participate in Upcoming March Investor Conferences


GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences:

TD Cowen 45th Annual Health Care Conference:

Fireside Chat

Date:

Tuesday, March 4, 2025



Time:

9:10 – 9:40 a.m. Eastern Time (ET)



Location:

Boston, MA



 

Conference

Event:

Investor Meetings



Date:

Tuesday, March 4, 2025





Leerink Partners 2025 Global Healthcare Conference:

Presentation

Date:

Tuesday, March 11, 2025



Time:

3:40 – 4:10 p.m. ET



Location:

Miami Beach, FL



 

Conference

Event:

Investor Meetings



Date:

Tuesday, March 11, 2025









Jefferies Biotech on the Beach Summit:

Conference

Event:

Investor Meetings



Date:

Wednesday, March 12, 2025



Location:

 

Miami Beach, FL

A webcast of the fireside chat and presentation will be available through the Events and Presentations page of the Company's website at ir.novavax.com, with replays available for 30 days after the conferences.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, including a protein-based nanoparticle and Matrix-M™ adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors

Luis Sanay, CFA

240-268-2022

ir@novavax.com

Media

Giovanna Chandler

202-709-5563

media@novavax.com

 

Novavax Logo (PRNewsfoto/Novavax)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-upcoming-march-investor-conferences-302387404.html

SOURCE Novavax, Inc.

Visuelle Wertentwicklung / Kursverlauf · Novavax
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
MIC: XNAS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942